100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Phathom Pharmaceuticals Elects Class I Directors at 2026 Annual Meeting
Reports First Quarter 2026 Financial Results and Provides Business Update
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Other Events
Reports Third Quarter 2025 Financial Results and Provides Business Update
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report